5d396a37-9b3d-4255-a3bd-f4a7c9480aee
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- E2F_TARGETS+0.470
- MYC_TARGETS_V2+0.440
- UNFOLDED_PROTEIN_RESPONSE+0.350
- MTORC1_SIGNALING+0.330
- CHOLESTEROL_HOMEOSTASIS+0.280
- MITOTIC_SPINDLE+0.280
- PEROXISOME+0.270
- WNT_BETA_CATENIN_SIGNALING+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.520
- INTERFERON_GAMMA_RESPONSE-0.520
- TNFA_SIGNALING_VIA_NFKB-0.490
- INTERFERON_ALPHA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.460
- INFLAMMATORY_RESPONSE-0.460
- ANGIOGENESIS-0.430
- MYOGENESIS-0.390
- IL6_JAK_STAT3_SIGNALING-0.380
- APOPTOSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-HQ-A2OF-01A-11R-A26T-07 | — | — | 0.925 |
| 2 | 236350e9-8964-42ae-8880-d2f2281ff993 | — | — | 0.899 |
| 3 | TCGA-33-A4WN-01A-11R-A262-07 | — | cohortSQ2 | 0.895 |
| 4 | e235012b-4b29-478a-abad-6a70cd949cfa | — | — | 0.892 |
| 5 | a8ce7460-8ccd-4638-a854-55c4068af6ec | — | — | 0.889 |
| 6 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.889 |
| 7 | MDT-AP-2956 | Med | Medulloblastoma | 0.886 |
| 8 | a1539e2f-42d6-4314-9ea0-e29635d9e76f | — | — | 0.884 |
| 9 | TCGA-22-4591-01A-01R-1201-07 | — | cohortSQ1 | 0.883 |
| 10 | 5ab068b1-411a-4083-a1ab-3ca7569a54a0 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |